Actilyse's price to rise 15% from next month

Afexon's price to receive 10% premium for 1 year

Potastine OD to maintain 30.4% premium...Romiplate’s price voluntarily cut by 1.5%

The price of Boehringer Ingelheim’s acute myocardial infarction treatment Actilyse Inj.

 

(alteplase) will rise 15% from next month after applying for drug pricing adjustments.

 

Aju Pharm’s acute back pain reliever (aceclofenac, eperisone hydrochloride) will newly receive a 10% premium for 1 year.

 

Also, the 30.4% premium pricing for Hanmi Pharmacueetical’s allergic rhinitis treatment Potastine OD Tab (bepotastine calcium dihydrate) will be maintained due to the small number of companies producing the same product, and Kyowa Kirin Korea voluntarily opted for a 1.5% reduction in the price of its Romiplate 250μg (romiplostim).

 

According to industry sources, the Ministry of Health and Welfare is working to amend the ‘drug reimbursement list and reimbursement ceiling price table’ to implement the changes above for implementation on December 1st.

 

First, Aju Pharm’s Afexon Tab has been newly listed with premium pricing for 1 year.

 

The premium pricing rate will be wet at 10%.

 

For incrementally modified combined new drugs, the government applies a 59.5% premium for first generics for one year from listing.

 

For drugs from innovative pharmaceutical companies, the premium is set at 68% of the original drug price in the first year, then subsequently lowered to 53.55% after the term is terminated.

 

The premium pricing for Hanmi Pharmaceutical’s Potastine OD Tab will be maintained for the time being due to the small number of companies manufacturing the same item.

 

The premium rate of the drug is set at 30.4%.

 

The government applies premium pricing to drugs when there are 1 or less companies that produce a drug with the same route of administration, ingredient, and formulation as the first-listed incrementally modified new drug.

 

However, if no other companies produce the same product even after the 5-year premium pricing period, the premium pricing is maintained until the number of companies becomes 2 or more.

 

On the other hand, some companies have opted for strategic price reductions for marketing, etc.

 

Kyowa Kirin Korea applied for drug pricing adjustments to reduce the price of its Romiplate 250μg by 1.5%, and the reduction will be applied from the next month.

 

Boehringer Ingelheim Korea applied for a price increase for its Actilyse Inj.

 

(alteplase), and after undergoing negotiations, the price of Actilyse will be raised by 15% for each strength from next month.

 

The application to adjust the ceiling price for price increases can be submitted when the drug is ▲essential to the treatment of patients, ▲has no alternatives, ▲is supplied by one company and its administration is cheaper than its alternatives.

 

After the drug passes deliberation by the Health Insurance Review and Assessment Service’s Drug Reimbursement Review and Assessment Service and undergoes drug pricing negotiations with the National Health Insurance Service.